Jakauto Ointment contains Tofacitinib 2% w/w, a potent Janus kinase (JAK) inhibitor indicated for the topical treatment of moderate to severe plaque psoriasis in adult patients. Tofacitinib modulates the immune response by selectively inhibiting JAK enzymes involved in the signaling pathways of pro-inflammatory cytokines, thereby reducing inflammation and keratinocyte proliferation characteristic of psoriatic lesions. Jakauto Ointment is applied directly to the affected skin areas, providing targeted therapeutic effects while minimizing systemic exposure. Clinical studies have demonstrated significant improvement in lesion severity, scaling, and erythema with consistent use over a prescribed treatment period. The ointment should be used as directed by a healthcare professional, typically applied twice daily to clean, dry skin. Patients should avoid contact with eyes, mucous membranes, and open wounds. Common adverse effects may include mild local irritation, itching, or redness at the application site. Caution is advised in patients with a history of hypersensitivity to Tofacitinib or any excipients in the formulation. Jakauto Ointment is contraindicated in individuals with active infections or immunocompromised states. Regular monitoring by a healthcare provider is recommended to assess treatment response and detect any potential adverse reactions. This medication should be stored at controlled room temperature, away from direct light and moisture.